The monoclonal anti-VEGF antibody Bevacizumab, which was the first drug targeting the VEGF pathway, did not reach promising results in overall survival of gastric cancer patients in the AVAGAST clinical trial, however, it is now approved for first- and/or second-line treatment of a variety of tumors including colorectal cancer [191]. Here, VEGFA is linked to gastric cancer.